Features of pathogenesis and treatment of breast cancer in the works of modern oncologists
DOI:
https://doi.org/10.15587/2519-4798.2020.204109Keywords:
breast cancer, new treatment approaches, the impact of high technology, targeted drugs, cancer stem cellsAbstract
To increase the effectiveness of treatment for breast cancer, representatives of various oncological schools use various approaches and scientific results obtained using high technologies, as evidenced by the analysis of scientific publications of specialists.
The aim of this literature review was to analyze the influence of some scientific achievements using high technologies on modern ideas of oncologists about the pathogenesis of breast cancer and new approaches to increasing the efficiency of its treatment.
Material and research methods. Scientific articles in journals specializing in Oncology, materials of scientific conferences, Internet resources
Research results and their discussion. Unsatisfactory results of the treatment of breast cancer, frequent relapses of this pathology, high mortality, on the one hand, and the results of scientific studies using high technologies, on the other hand, led oncologists to search for new approaches to solving the problem by improving surgical, medicinal and radiation treatments.
Conclusions. The search for new approaches to solving the issue of increasing the effectiveness of breast cancer treatment is carried out in different directions: in the field of improving surgical treatment methods, drug methods, taking into account inhibitors of immune control points, new drugs for targeted therapy and the theory of cancer stem cells. The development of new approaches to the treatment of breast cancer has great prospects in addressing the issue of increasing the effectiveness of its treatment
References
- Merabishvili, V. M. (2013). Epidemiologiia i vyzhivaemost bolnykh rakom molochnoi zhelezy. Voprosy onkologii, 59 (3), 314–19.
- Andriiv, A. V., Romanchuk, V. R., Kryzhanivska, A. Ye. (2015). Osoblyvosti epidemiolohii ta kliniko-morfolohichnykh kharakterystyk raku molochnoi zalozy u khvorykh iz riznykh ekolohichnykh zon Ivano-Frankivskoi oblasti. Onkolohiia, 17 (3), 156–161.
- Rak v Ukraini, 2012–2013 (2014). Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby. Biuleten Natsionalnoho kantser-reiestru Ukrainy, 15, 120.
- Sadchikova, M. V., Siniavina, L. V., Otchenash, N. N. (2019). Rol gormonoterapii v lechenii rannego raka molochnoi zhelezy u premenopauzalnykh zhenschin. Mіzhnarodnii medichnii zhurnal, 2, 40–44.
- Shatova, Iu. S. (2015). Kliniko-epidemiologicheskie i gormonalno-metabolicheskie zakonomernosti razvitiia raka molochnoi zhelezy u zhenschin v razlichnye reproduktivnye periody zhizni. Rostov-na-Donu, 45.
- Dergunova, Y. A., Podionov, V. V., Bozhenko, V. K., Kometova, V. V., Dardyk, M. V. (2018). Clinical, morphological, and molecular genetic predictors of metastatic lesions in the regional lymph nodes in breast cancer. Advances in Molecular Oncology, 5(3), 8–16. doi: http://doi.org/10.17650/2313-805x-2018-5-3-8-16
- Krivorotko, P. V., Dashian, G. A., Paltuev, R. M., Zernov, K. IU., Bessonov, A. A. et. al. (2016). Biopsiia signalnykh limfaticheskikh uzlov pri rake molochnoi zhelezy. Zlokachestvennye opukholi, 1 (4), 4–8.
- Zikiriakhodzhaev, A. D., Saribekian, E. K., Ablicova, N. V., Ermoschenkova, M. V., Zapirov, G. M., Mazo, M. L. et. al. (2018). Rak molochnoi zhelezy posle augmentacionnoi mammoplastiki. Khirurgicheskaia taktika. Voprosy onkologii, 64 (6), 768–773.
- Pavlikova, O. A., Koliadina, I. V., Komov, D. V., Vishnevskaia, IA. V., Poddubnaia, I. V. (2017). Faktory-prediktory dostizheniia polnogo lekarstvennogo patomorfoza pri neoadiuvantnoi khimioterapii pervichno-operabelnogo raka molochnoi zhelezy. Sovremennaia onkologiia, 19 (1), 24–29.
- Semiglazov, V. F. (2013). Novye podkhody k lecheniiu raka molochnoi zhelezy. Voprosy onkologii, 59 (3), 288–291.
- Bozhok, A. A., Topuzov, E. E., Semiglazov, V. F., Klimov, N. A., Kasianovy, M. N., Ovsianikov, A. A. (2013). Vozmozhnosti khirurgicheskogo lecheniia pri disseminirovannom rake molochnoi zhelezy. Voprosy onkologii, 59 (3), 320–327.
- Semiglazov, V. F., Bozhok, A. A., Semiglazova, T. IU., Vasilev, A. G., Manikhas, A. G., Semiglazov, V. V. et. al. (2013). HER2-pozitivnii rak molochnoi zhelezy: standartnoe i dvoinoe targetnoe lechenie. Voprosy onkologii, 59 (3), 341–346.
- Goncharuk, E. (2019). Novye vozmozhnosti v lechenii metastaticheskogo RGZH v postmenopauze: klinicheskii obzor kliuchevykh issledovanii. Clinical Oncology, 9 (2), 68–73. doi: http://doi.org/10.32471/clinicaloncology.2663-466x.39.22815
- Krzhivickii, P. I., Novikov, S. N., Kanaev, S. V., Klicenko, O. A., Ilin, N. D., Popova, N. S. et. al. (2017). OFEKT-KT v diagnostike metastaticheskogo porazheniia limfaticheskikh uzlov u bolnykh rakom molochnoi zhelezy. Voprosy onkologii, 63 (2), 261–266.
- Vasilev, A. G., Semiglazov, V. F., Semenov, I. I., Semiglazov, V. V. (2010). Znachenie klinicheskikh i luchevykh metodov ocenki kharaktera i stepeni rasprostraneniia opukholevogo processa v planirovanii lecheniia raka molochnoi zhelezy. Protokol 473-go zasedaniia Nauchnogo obschestva onkologov Sankt-Peterburga i Leningradskoi oblasti Doklad 1. Voprosy onkologii, 56 (3), 262–271.
- Gurbanov, S. S., Macko, D. E., Kanaev, S. V., Semiglazov, V. F. (2009). Faktory riska vozniknoveniia mestnoregionarnykh recidivov raka molochnoi zhelezy posle organosokhraniaiuschikh operacii. Voprosy onkologii, (1), 33–37.
- Semiglazov, V. F. (2011). Strategiia lecheniia raka molochnoi zhelezy, osnovannaia na vydelenii biologicheskikh podtipov. Voprosy onkologii, 5, 542–552.
- Gorbacheva, O. Iu., Ivashkov, V. Iu., Sobolevskii, V. A., Krokhina, O. V., Mekhtieva, N. I. K. (2018). Rannii rak molochnoi zhelezy: znachenie biologicheskogo podtipa opukholi dlia vybora khirurgicheskoi taktiki lecheniia (obzor literatury). Voprosy onkologii, 64 (6), 716–721.
- Lialkin, S. A., Syvak, L. A., Khranovska, N. M., Verovkina, N. O. (2019). Role of TLR-2, TLR-4, TLR-9 gene polymorphism in prognosis of triple negative breast cancer. Clinical Oncology, 9 (2), 106–109. doi: http://doi.org/10.32471/clinicaloncology.2663-466x.39.22677
- Goncharuk, E. (2019). Endokrinoterapiia raka molochnoi zhelezy v period pre- i postmenopauzy: sootvetstvie klinicheskoi praktiki dokazatelnoi medicine. Clinical Oncology, 9 (2), 132–135. doi: http://doi.org/10.32471/clinicaloncology.2663-466x.40.23202
- Naskhletashvili, D. R., Gorbunova, V. A., Moskvina, E. A. (2013). Sovremennye vozmozhnosti targetnoi terapii v lechenii raka molochnoi zhelezy s giperekspressiei Her2/neu i s metastaticheskim porazheniem golovnogo mozga. Voprosy onkologii, 59 (3), 347–351.
- Kongress ESMO 2018: TOP novostei onkologii (2018). Medicinskii Vestnik, 3-4, 15.
- Shevchenko, R. (2018). Dennis Slemon: v onkologii novaia era. Medicinskii Vestnik, 3-4, 4-5.
- Vladimirova, L. Y. V., Popova, I. L. P., Abramova, N. A. A., Storozhakova, A. E. S., Tikhanovskaya, N. M. T. et. al. (2019). Trastuzumab emtanzin in the treatment of HER2-positive metastatic breast cancer in patients with visceral crisis. Pharmateca, 7, 58–63. doi: http://doi.org/10.18565/pharmateca.2019.7.58-63
- Marshutina, N. V., Sergeeva, N. S., Alentov, I. I., Kaprin, A. D. (2019). Autoantibodies against tumor-associated antigens as one class of serological markers. Advances in Molecular Oncology, 6 (1), 10–17. doi: http://doi.org/10.17650/2313-805x-2019-6-1-10-17
- Kukushkina, S. N., Filchakov, F. V. (2018). Kletki adaptivnogo immuniteta: vozmozhnost ispolzovaniia v kachestve prognosticheskikh faktorov v klinicheskikh issledovaniiakh raka grudnoi zhelezy (obzor literatury). Klinicheskaia onkologiia, 8 (1), 28–33.
- Sivak, L. A., Verevkina, N. O. (2017). Immunoterapiia pri rake grudnoi zhelezy: znachenie, perspektivy, problemy. Klinicheskaia onkologiia, 26 (2), 56–61.
- Kukushkina, S. N., Filchakov, F. V. (2017). Kletki vrozhdennogo immuniteta i ikh sviaz s prognozom zabolevaniia u bolnykh rakom grudnoi zhelezy (obzor literatury). Klinicheskaia onkologiia, 28 (4), 82–87.
- Boeva, L. (2018). HR+ HER2- mRMZH: innovacii v rukakh masterov. Medicinskii Vestnik, 3-4, 14–15.
- Kovalenko, E. I., Artamonova, E. V. (2019). Nab-paclitaxel in Treatment of Metastatic Breast Cancer. Medical Alphabet, 2 (17), 12–18. doi: http://doi.org/10.33667/2078-5631-2019-2-17(392)-12-18
- Durairaj, C., Ruiz-Garcia, A., Gauthier, E. R., Huang, X., Lu, D. R., Hoffman, J. T. et. al. (2018). Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anti-Cancer Drugs, 29 (3), 271–280. doi: http://doi.org/10.1097/cad.0000000000000589
- Maidanevich, N. N., Sivak, L. A., Melnichenko, I. V. (2018). Prognozirovanie razvitiia emeticheskogo sindroma khimioterapii pri skheme TS s metastaticheskim rakom molochnoi zhelezy. Evraziiskii onkologicheskii zhurnal, 6 (3-4), 675–682.
- Semiglazova, T. Y., Sorokina, I. V. S. (2019). Prognostic and predictive values of the PIK3CA gene mutation in patients with breast cancer. Pharmateca, 7, 10–20. doi: http://doi.org/10.18565/pharmateca.2019.7.10-20
- Piatchanina, T. V. (2016). Fundamentalnye znaniia kak osnova novovvedenii v klinicheskoi onkologii. Daidzhest dokladov sekcii «Konceptualnye voprosy eksperimentalnoi i fundamentalnoi onkologii» na XIII sezde onkologov i radiologov Ukrainy (26–28 maia 2016 g.). Onkologiia, 18 (2), 156–159.
- Raskin, G. A., Orlova, R. V., Protasova, A. E., Petrov, S. V., Ivanova, A. K., Pozharisskii, K. M. (2013). Rol stvolovykh rakovykh kletok, khemokinov i ikh receptorov v kancerogeneze, recidivirovanii i metastazirovanii opukholei. Voprosy onkologii, 59 (6), 694–700.
- Kazanceva, P. V., Slonimskaia, E. M., Cyganov, M. M., Ibragimova, M. K., Doroshenko, A. V., Tarabanovskaia, N. A., Litviakov, N. V. (2019). Predektivnaia i prognosticheskaia znachimost amplifikacii genov stvolovosti v opukholi molochnoi zhelezy bolnykh, poluchavshikh neoadiuvantnuiu khimioterapiiu. Farmateka, 7, 50–56. doi: http://doi.org/10.18565/pharmateca.2019.7.50-56
- Morel, A.-P., Lièvre, M., Thomas, C., Hinkal, G., Ansieau, S., Puisieux, A. (2008). Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition. PLoS ONE, 3 (8), e2888. doi: http://doi.org/10.1371/journal.pone.0002888
- Dashian, G. A., Semiglazov, V. F., Donskikh, R. V., Vorotnikov, V. V., Apollonova, V. S., Semiglazova, T. Iu. (2015). Rol stvolovykh kletok raka molochnoi zhelezy v metastazirovanii. Voprosy onkologii, 61 (2), 169–173.
- Smirnova, I. A., Orlova, N. V., Kharitonova, A. A.,Zamulaeva, I. A., Kiseleva, M. V. (2018). Kolichestvennii analiz opukholevykh stvolovykh kletok u bolnykh trizhdy negativnym rakom molochnoi zhelezy. Evraziiskii onkologicheskii zhurnal, 6 (3-4), 906–907.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Tamara Tamm, Grigory Oleinik, Oleksandra Prokopyuk, Maryna Sadchykova, Yuriy Vinnik
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.